A specialty pharmaceutical company focused on injectable products across oncology, anti-infectives, and critical care, with a strong presence in the U.S. hospital market.
Control investment with active ownership and operational leadership. Dr. Vishy Chebrol, Parami’s Managing Partner, serves as CEO of Sagent — directly leading the company’s transformation.
Segment: Hospital Generics | Market: United States | Type: Control Buyout
A leading vaccines and biologics platform with a strong legacy in developing and manufacturing affordable vaccines for global markets, with WHO-recognized quality standards.
Strategic investment to support platform expansion and operational scale-up, with Parami deploying its vaccine manufacturing expertise to accelerate growth across global markets.
Segment: Vaccines | Market: Global | Type: Platform Investment
Operational partnership focused on building manufacturing capacity and technical capability to position Shantha Biologics as a preferred CDMO and commercial supply partner globally.
Segment: Biologics | Market: Global | Type: Platform Build
A specialized pharmaceutical manufacturing platform supporting complex formulations and global pharmaceutical customers, with established capabilities in regulated manufacturing environments.
Strategic operational partnership focused on expanding Gland’s capabilities into high-value regulated market formulations and building its position as a preferred complex chemistry and manufacturing partner.
Segment: Formulations | Market: Regulated | Type: Growth Investment